1. Home
  2. CYCC vs ARTL Comparison

CYCC vs ARTL Comparison

Compare CYCC & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • ARTL
  • Stock Information
  • Founded
  • CYCC 1992
  • ARTL 2011
  • Country
  • CYCC United States
  • ARTL United States
  • Employees
  • CYCC N/A
  • ARTL N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • ARTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYCC Health Care
  • ARTL Health Care
  • Exchange
  • CYCC Nasdaq
  • ARTL Nasdaq
  • Market Cap
  • CYCC 3.6M
  • ARTL 3.8M
  • IPO Year
  • CYCC N/A
  • ARTL N/A
  • Fundamental
  • Price
  • CYCC $0.34
  • ARTL $1.16
  • Analyst Decision
  • CYCC Strong Buy
  • ARTL Strong Buy
  • Analyst Count
  • CYCC 1
  • ARTL 2
  • Target Price
  • CYCC $11.00
  • ARTL $5.50
  • AVG Volume (30 Days)
  • CYCC 404.4K
  • ARTL 33.2K
  • Earning Date
  • CYCC 03-18-2025
  • ARTL 03-24-2025
  • Dividend Yield
  • CYCC N/A
  • ARTL N/A
  • EPS Growth
  • CYCC N/A
  • ARTL N/A
  • EPS
  • CYCC N/A
  • ARTL N/A
  • Revenue
  • CYCC $74,000.00
  • ARTL N/A
  • Revenue This Year
  • CYCC N/A
  • ARTL N/A
  • Revenue Next Year
  • CYCC $88.68
  • ARTL N/A
  • P/E Ratio
  • CYCC N/A
  • ARTL N/A
  • Revenue Growth
  • CYCC N/A
  • ARTL N/A
  • 52 Week Low
  • CYCC $0.30
  • ARTL $0.91
  • 52 Week High
  • CYCC $4.00
  • ARTL $1.70
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 46.57
  • ARTL 43.72
  • Support Level
  • CYCC $0.32
  • ARTL $1.15
  • Resistance Level
  • CYCC $0.38
  • ARTL $1.24
  • Average True Range (ATR)
  • CYCC 0.02
  • ARTL 0.10
  • MACD
  • CYCC 0.00
  • ARTL -0.02
  • Stochastic Oscillator
  • CYCC 50.00
  • ARTL 2.50

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Share on Social Networks: